Edesa Biotech (EDSA) Other Non-Current Liabilities (2020 - 2023)
Edesa Biotech (EDSA) posted Other Non-Current Liabilities of $44340.0 for Q1 2023, little changed sequentially from $44280.0 in Q4 2022, and down 7.57% YoY from $47970.0 in Q1 2022.
Edesa Biotech (EDSA) Other Non-Current Liabilities (2020 - 2023) Analysis & Trends
Edesa Biotech has reported Other Non-Current Liabilities for 4 years, with the latest figure at $44340.0 in Q1 2023.
- Quarterly Other Non-Current Liabilities fell 7.57% year-over-year to $44340.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $44340.0 (down 7.57% YoY) and the FY2022 annual result came in at $43662.0, down 7.5% from the prior year.
- Other Non-Current Liabilities steadied at $44340.0 in Q1 2023 per EDSA's latest filing, from $44280.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $48396.0 in Q2 2021 and troughed at $29320.0 in Q2 2020.
- A 4-year average of $43633.8 and a median of $46809.0 in 2020 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2023: Other Non-Current Liabilities surged 65.06% in 2021, then slipped 7.57% in 2023.
- Over 4 years, Other Non-Current Liabilities stood at $47082.0 in 2020, then advanced by 0.34% to $47244.0 in 2021, then retreated by 6.27% to $44280.0 in 2022, then gained by 0.14% to $44340.0 in 2023.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $44340.0, $44280.0, and $43662.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 44,340.00 |
| Dec 31, 2022 | 44,280.00 |
| Sep 30, 2022 | 43,662.00 |
| Jun 30, 2022 | 46,536.00 |
| Mar 31, 2022 | 47,970.00 |
| Dec 31, 2021 | 47,244.00 |
| Sep 30, 2021 | 47,202.00 |
| Jun 30, 2021 | 48,396.00 |
| Mar 31, 2021 | 47,646.00 |
| Dec 31, 2020 | 47,082.00 |
| Sep 30, 2020 | 29,928.00 |
| Jun 30, 2020 | 29,320.00 |